Refine Search

New Search

Result: 1

(searched for: (title:(A Review: Artemisinin-Based Combination Therapies [ACTs] and K13 Polymorphism)
Save to Scifeed
Page of 1
Articles per Page
by
Show export options
  Select all
Aqeel Ahmad,
Journal of Environmental & Life Sciences, Volume 6, pp 088-091; doi:10.37871/jels1124

Abstract:
Malaria is caused by four plasmodium species in humans (P. falciparum, P. vivax, P. malariae and P. ovale) which spread from one person to another via the bite of female Anopheles mosquito. P. falciparum causes most deaths from malaria [1] and is most prevalent on the African continent whereas P. vivax has a wider geographical distribution [2]. According to the latest WHO estimates, released in December 2015, there were 214 million cases of malaria in 2015 and 438,000 deaths [3]. Existing strategies to control malaria include vector control, chemoprevention and case management [4]. Without a fruitful antibody that would offer security against malaria, we have to depend on anti-malarial prescription to treat just as lessen the odds of getting the disease [5-8]. Artemisinin in mix with other moderate acting medications is suggested for the treatment of P. falciparum [9,10].
Page of 1
Articles per Page
by
Show export options
  Select all
Back to Top Top